We developed and validated two clinical prediction tools to identify contacts at high-risk for TB disease using clinical and demographic information obtained from the patient and household contact. These tools perform similarly to more costly and less feasible biomarkers.
INTRODUCTION
Worldwide, an estimated 10.0 million people developed tuberculosis (TB) disease in 2017, of whom only 64% were detected and reported to the World Health Organization (WHO) [1] .
Among diagnosed TB patients, self-reported delays in diagnosis has been estimated to range from one to six months after symptom onset [2] , suggesting that by the time an infectious patient is put on treatment, many close contacts of that patient will have been exposed to Mycobacterium tuberculosis (M.tb) and at risk of developing active TB. The diagnosis of a TB patient thus provides a window of opportunity for TB clinics to screen for and treat active TB among patient contacts and to offer preventive therapy to those at risk of progressing to active disease.
Unfortunately, contacts are routinely lost from the contact screening and preventive therapy care cascades (Figure 1 ). While many national guidelines recommend systematic screening of contacts for TB disease [3] [4] [5] , dropouts in high-burden settings are substantial. For example, the proportion of targeted contacts screened for TB disease was 8% of under-5 year olds in Indonesia [6] ; 14% of under 15-year olds in India [7] ; and 5% of all household contacts in urban Uganda [8] . Similarly, while many national guidelines recommend preventive therapy for subsets of contacts who screen negative for TB disease [5, 9] , fewer than 20% of contacts 5 years or younger initiated therapy in India and rural Malawi despite the fact that national guidelines specified treatment for this group [7, 10] . A recent WHO guideline recommended expanding preventive therapy to household contacts ≥5 years in high-incidence countries [9] , but dropouts in this age category have not yet been assessed [11] . Implementation barriers to contact screening and preventive therapy act at both the individual and healthcare system levels. For those targeted for screening, a lack of knowledge about TB transmission, perceived low risk of infection and disease, and long wait times at clinics 7 have been identified as reasons for losses at different steps in the cascades [11] [12] [13] . For TB clinics, identified barriers include insufficient time and space for counseling, lack of funds for contacts travel [13] , and low health-provider knowledge about the benefits and risks of preventive therapy [11] .
One way to address some of these barriers would be to use clinical prediction tools to quantify individual TB risks for contacts. Here, we describe two prediction tools to estimate and communicate the risk of TB to contacts and clinics ( Figure 1 ). We designed the first tool to estimate the risk of co-prevalent TB among household contacts at the time of index patient diagnosis and the second to estimate the risk of subsequent progression to TB.
METHODS
Between September 2009 and August 2012, we conducted a prospective cohort study of household contacts of pulmonary TB patients aged ≥16 years in Lima Province, Peru. Data collected at baseline included sociodemographic and clinical characteristics of both index patients and contacts (Table 1) . We tested contacts for LTBI using tuberculin skin tests (TST). Contacts who reported symptoms of TB disease at the time of enrollment were referred to their local health clinic for clinical evaluation and diagnosis of TB disease. Contacts were then followed for 12 months. Incident TB were identified at routine household visits or from medical records at the participating study clinics. The design of this study has been reported previously [14, 15] .
We developed two multivariable models to predict TB disease among contacts using these data: the first model predicts a TB diagnosis within 14 days after index patient diagnosis (co-prevalent TB); the second model predicts a one-year incident TB diagnosis among contacts in whom TB had been ruled out at baseline (incident TB).
We built the TB-Coprevalent Model including those baseline characteristics of the index patient, the household, and the contact that could be readily obtained at the time the index patient was diagnosed. We trained the model on the subset of contacts from the districts of North Lima, East Lima and Rimac (training sample, Figure 2 ). We initially included 24 candidate predictors that had been previously associated with risk of TB (Table 2) [16] . We then used a 10-fold cross validation procedure to fit a multivariable least absolute shrinkage and selection operator (Lasso) logistic regression model with the glmnet package [17] in R (3.5.0), imputing missing data for candidate predictors (Supplementary materials). We used out-of-sample model deviance in cross validation to select an optimal Lasso shrinkage parameter for fitting the final logistic regression training model. We assessed the goodness of fit of this final model by computing the area under a receiver operating characteristic curve (c statistic, AUC) and the Hosmer-Lemeshow test, where low p values (e.g. p<0.05) indicate poor calibration. We used the coefficients from this final model to compute a risk score for co-prevalent TB by dividing its Lasso coefficient for each predictor by the largest coefficient among all predictors, multiplied by 10, and rounded to the nearest integer.
We evaluated the score's ability to classify patients by comparing observed and predicted risks within three risk groups. We then estimated the score's sensitivity and specificity using plausible cut-offs indicated by its distribution. Finally, we validated the score among the subset of contacts diagnosed within Central Lima (validation sample, Figure 2 ). We tested for homogeneity of baseline characteristics between the validation and the training sample using  2 tests for categorical variables, Wilcoxon rank-sum test for continuous variables with non-normal distributions, and t-test for body mass index (BMI). To further illustrate the utility of the risk score in aiding decision-making processes during contact screening, we compared the relative utility curves [18] (Supplementary materials) of the TB-Coprevalent Model risk score and the current WHO recommendations for contact investigation in low-and middle-income countries [3] , assuming that the cost of index patient surveys is negligible relative to the utility of identifying a co-prevalent TB patient.
Using the same approach, we next developed a prediction model for one-year incident TB (TB-Incident Model) among contacts aged ≥20 years who did not have co-prevalent disease and had not received preventive therapy. (We note that Peru national TB policy specifies that preventive therapy is only offered to contacts <20 years and to individuals with specified co-morbidities [19] ). Here, we included the variables used in the previous model as well as contact-specific information that might be routinely collected during screening including socioeconomic status, body mass index and diabetes mellitus, and the presence/number of visible scars from BCG immunization ( Table 3 ). After obtaining a final Lasso logistic regression model in the training sample, we computed the risk score for one-year incident TB by dividing the Lasso coefficients of predictors by the absolute value of the coefficient of BMI and rounded to the nearest integer to ensure one unit difference in BMI translates into one unit change in the risk score.
We added 30 to the sum of predictor scores in order to have a score distribution similar to the TB-Coprevalent Model score. We conducted a sensitivity analysis in which we added TST as a candidate predictor before the Lasso procedure and compared the performance of both models (the TB-TST (Incident) Model). We also validated a previously developed model (Saunders risk score) [20] for predicting one-year incident TB in our cohort. We classified contacts into three arbitrary risk groups based on their incident TB risks and calculated the net reclassification improvement (NRI) [21] comparing our model to the Saunders risk score. Finally, we compared the relative utility curves of 1) TB-Incident Model, 2) TB-TST (Incident) Model, 3) Saunders risk score [20] , 4) LTBI identification based on TST results alone, and 5) the current WHO recommendation for preventive therapy [9] , and computed test thresholds for the difference in utility between the TB-Incident Model and the TB-Incident TST Model.
RESULTS

TB-Coprevalent Model risk score
The training sample for the TB-Coprevalent Model included 10,062 contacts of adult pulmonary TB patients ( Figure 2 ), of which 2.0% (198) were found to have co-prevalent TB (Table 1) . Of the 24 candidate predictors shown in Table 2 , 17 remained in the best Lasso model which had an AUC of 0.86 (95% CI: 0.83 -0.89) ( Figure 3 ) and a Hosmer-Lemeshow test of p=0.72. The final risk score included the 12 predictors shown in Table 2 . The risk scores were distributed bimodally ( Figure 4b ): the majority of contacts (94%) had scores <6 and 0.7% of this group had co-prevalent TB, while 18.4% of those with scores between 6 and 10 and 36.5% of those with scores >10 had co-prevalent TB (Figure 4c ). We found no significant differences between predicted and observed prevalences (SFigure 1, STable 1). When we considered those with scores ≥6 as the high-risk group, our tool had 65% sensitivity and 96% specificity in identifying contacts with co-prevalent disease, with a positive predictive value (PPV) of 22.4% and a negative predictive value (NPV) of 99.3% (Table 4 ).
Contacts in the validation sample (n=3,982) had a higher prevalence of co-prevalent TB (2.5%, n=98) than those in the training sample (2.0%, p=0.08) ( Table 1 ). The validation AUC was 0.83 (0.78 -0.88) ( Figure 3 ) and the Hosmer-Lemeshow statistic was p=0.005. Calibration plots ( Figure 4d , SFigure 1, STable 1) indicate that the score tended to underestimate co-prevalent TB risks for contacts in the median risk category. The relative utility of using the TB-Coprevalent Model to inform contact screening is substantially higher than the WHO recommendation ( Figure 5 ) [3] ; at a risk threshold of 5%, the relative utility of following the TB-Coprevalent Model is 20 percentage points higher than following the WHO recommendation.
TB-Incident Model risk score
Among 5,298 adult contacts included in the TB-incidence model (Figure 2 ), 1.8% (n=97) developed incident TB within one year of enrollment. Of 27 candidate predictors (Table 3) (Table 3) . After we rounded model coefficients, the score was normally distributed in the training sample ( Figure 6b ), with scores <6 in 62% of contacts, of whom 0.9% developed TB; scores between 6 and 10 in 29% of contacts, of whom 2.6% developed TB; and scores >10 in 9.2% of contacts, of whom 5.5% developed TB (Figure 6c ). Table 4 shows the sensitivity, specificity, PPV and NPV at several arbitrary cut-off points. The Saunders' score [20] gave an AUC of 0.65 (0.60 -0.69) in our cohort; it overestimated risk for the high and medium risk contacts and underestimated risk in the low risk group (SFigure 3). Compared to the Saunders' score the TB-Incident Model classified more contacts into risk categories that better represent their risk of incident TB (Table 5) : the reclassification improvement [21] using the TB-Incident Model risk score is 13.1% for contacts who progressed to TB and 4.6% for contacts who did not progress, giving an NRI of 17.7%.
For risk thresholds between 1% and 5%, i.e. for a person who would only get preventive therapy if he or she had a 1-5% risk of 1-year incident TB or higher, treatment decisions informed by the TB-Incident Model gave at least 5-10% higher relative utility compared to all previous methods ( Figure 7 ). Including the TST in the TB-Incident Model was only worthwhile if one is willing perform at least 800 TSTs to find a single true positive case. For risk thresholds below 1%, different tests yielded similar utilities whilst for risk thresholds above 5%, test utilities were no better than treating no one in the population.
DISCUSSION
We developed two tools that are predictive of TB risks for household contacts of adult pulmonary TB patients using clinical and demographic predictors that are easily collected in clinical settings, without the need for obtaining measurements that would delay contact screening and preventive therapy. The TB-Coprevalent Model uses information that could be obtained from patients at the time of their TB diagnosis to distinguish high and low risk contacts. The
TB-Incident Model incorporates additional contact-specific demographic variables and predicts
the probability of an adult contact progressing to active disease within one year of the diagnosis of the index patient. Both tools performed well in terms of the AUC and were validated in a geographically and demographically distinct sample of contacts. Clinical decisions for contact screening and preventive therapy based on predicted risks from these tools might be more effective in reducing secondary TB cases than current practice.
Although investigators have previously developed algorithms for screening for TB disease with symptom questionnaires and/or chest radiography [22] [23] [24] , to our knowledge, the TB-Coprevalent Model is the first validated prediction model for co-prevalent disease among household contacts. A limited number of studies have also incorporated TB risk factors into screening algorithms; these target specific high-risk groups such as symptomatic individuals [24] , hospital inpatients [25] , HIV-infected individuals [26, 24] , immigrants [27] , and prisoners [28] , but none focus on household contacts. Whereas most other tools require that the relevant information is obtained directly from the individuals being screened, the TB-Coprevalent Model can be used before the contacts are engaged in the health care system.
In contrast to screening for co-prevalent disease, the prediction of incident TB often involves both epidemiological risk factors and/or biomarkers such as TST, IGRA, and, more recently, RNA-based signatures. A systematic review and meta-analysis of TST and IGRA to predict TB progression in high risk groups estimated summary sensitivities and specificities of 72% and 50% respectively for ELISpot and 72% and 41% for the TST [29] . Blood RNA signatures have performed similarly in several African cohorts [30, 31] ; the most recent 4-gene signature had an AUC of 0.69 when validated among household contacts [31] .
Tools that rely on epidemiological and clinical risk factors of the index cases and their contacts have performed equally well and, in some cases, better than biomarkers. In one study, the addition of epidemiological indicators to the TST improved the prediction of TB disease among child contacts from an AUC of 0.80 to 0.87 [32] . Another recent study developed and assessed the performance of a tool that used a range of risk factors to stratify adult contacts of smear-positive TB patients by their risk of developing TB up to 10 years post-enrollment [20] . With AUCs of 0.72 in the training cohort and 0.67 in the validation cohort, this tool performs similarly to the TB-Incident Model. Although both tools were developed and validated in Peruvian cohorts, our model pertains to contacts of all index pulmonary TB patients regardless of microbiological confirmation, while the previous model focuses on contacts of smear-positive TB patients. In addition, our model did not use household socioeconomic status which may be difficult to rapidly assess in practice.
Although the AUCs for predicting incident TB are reasonable, none of the currently available tests have high prognostic value despite the strong associations between the identified markers or scores and TB incidence [29] . In our study, the distribution of the TB-Incident Model risk score for contacts with and without incident TB overlapped substantially ( Figure 6b ). Therefore, although the TB-Incident Model is similar to other tools [29, 33] in having a relatively a high NPV, the low PPV means that there are comparable numbers of TB cases in the low-risk and high-risk groups. Nonetheless, the value of using an individualized TB risk score may go beyond efficiently prioritizing interventions; in randomized trials for cancer screenings, communicating individualized cancer risk scores to patients resulted in higher adherence to recommended protocols than providing them with general risk information [34] . Because low awareness of TB risks has been associated with both delays in care-seeking behavior and poor adherence to treatment and preventive therapy [35, 11] , score-based tools might empower contacts to make informed decisions on initiating or adhering to TB screening and preventive therapy.
We note some limitations to our study. First, although the TB-Coprevalent Model uses information about contacts that we believe could be obtained directly from index patients, the data used in this study was collected from the contacts during household visits. It is possible that index patients undergoing an initial diagnostic work-up for TB may provide different information on contact characteristics than the contacts provided. To minimize this potential misclassification, we collapsed some categorical variables into coarser dichotomous predictors such as coughing and smoking that might be more easily reported by an index patient, and we classified our continuous BMI variable into three categories: normal, overweight and underweight. In practice, collecting contact information from the index patient could also be improved by asking the patient to communicate with their contacts by phone or text during the initial encounter. However, without actually implementing this strategy, it is difficult to assess its feasibility. Secondly, we assumed that index patients are aware of their HIV status. While TB patients are routinely tested for HIV if they don't already know their status, the results of these tests are often not available at the time of TB diagnosis. However, the index patient's HIV status is only a weak predictor for co-prevalent TB and does not impact the predictive ability of the model when we removed it in a sensitivity analysis (results not shown). Our cohort differed from what might be encountered in other settings in that HIV prevalence was extremely low and HIV status of the exposed contact was not found to be a significant predictor in our model. In higher HIV burden areas, the HIV status of contacts would be expected to contribute substantially to the risk of progression and our tools may require further modification in these settings.
In summary, we developed two tools to predict TB in household contacts of index TB patients on the basis of easily obtained information and showed that in Lima, Peru, the performance of these tools may be comparable to biomarkers that are both more costly and less feasible than this approach.
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